Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 881

1.

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M.

Am J Ophthalmol. 2007 Apr;143(4):566-83.

PMID:
17386270
2.

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.

Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M.

Am J Ophthalmol. 2009 Jul;148(1):43-58.e1. doi: 10.1016/j.ajo.2009.01.024. Epub 2009 Apr 18.

PMID:
19376495
3.

Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.

Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.

Ophthalmology. 2009 Sep;116(9):1740-7. doi: 10.1016/j.ophtha.2009.05.033. Epub 2009 Jul 29.

PMID:
19643484
4.

Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.

Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.

Ophthalmology. 2009 Dec;116(12):2393-9. doi: 10.1016/j.ophtha.2009.05.039. Epub 2009 Oct 7.

PMID:
19815292
5.

Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.

Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study Group..

Ophthalmology. 2007 Oct;114(10):1868-75. Epub 2007 Jul 12.

PMID:
17628683
6.

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.

Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG.

Ophthalmology. 2009 Sep;116(9):1731-9. doi: 10.1016/j.ophtha.2009.05.024. Epub 2009 Jul 29.

PMID:
19643495
7.

Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration.

Lai TY, Chan WM, Liu DT, Lam DS.

Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1877-80. Epub 2007 Sep 28.

PMID:
17901972
8.

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N.

Ophthalmology. 2006 Apr;113(4):633.e1-4. Epub 2006 Feb 14.

PMID:
16483659
9.

Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.

Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N.

Retina. 2011 May;31(5):871-9. doi: 10.1097/IAE.0b013e3182003ca8.

PMID:
21358461
10.

Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.

Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ.

Ophthalmology. 2009 Sep;116(9):1755-61. doi: 10.1016/j.ophtha.2009.03.017. Epub 2009 Jun 27.

PMID:
19560206
11.

Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results.

Parravano M, Oddone F, Tedeschi M, Chiaravalloti A, Perillo L, Boccassini B, Varano M.

Retina. 2010 Jul-Aug;30(7):1017-24. doi: 10.1097/IAE.0b013e3181cfd3c6.

PMID:
20224469
12.

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.

Abraham P, Yue H, Wilson L.

Am J Ophthalmol. 2010 Sep;150(3):315-324.e1. doi: 10.1016/j.ajo.2010.04.011. Epub 2010 Jul 3.

PMID:
20598667
13.

Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A.

Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1165-71. doi: 10.1007/s00417-009-1089-3. Epub 2009 Apr 29.

PMID:
19404661
14.

Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.

Rouvas A, Petrou P, Ntouraki A, Douvali M, Ladas I, Vergados I.

Retina. 2010 Jun;30(6):893-902. doi: 10.1097/IAE.0b013e3181cd4894.

PMID:
20531142
15.

Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study.

Rouvas A, Petrou P, Vergados I, Pechtasides D, Liarakos V, Mitsopoulou M, Ladas I.

Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1609-16. doi: 10.1007/s00417-009-1138-y. Epub 2009 Jul 16.

PMID:
19609550
16.

Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.

Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE.

Am J Ophthalmol. 2009 May;147(5):831-7. doi: 10.1016/j.ajo.2008.12.005. Epub 2009 Feb 13.

PMID:
19217019
17.

Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.

Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A.

Graefes Arch Clin Exp Ophthalmol. 2009 Mar;247(3):311-8. doi: 10.1007/s00417-008-0995-0. Epub 2008 Nov 29.

PMID:
19043731
18.

Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration.

Bolz M, Simader C, Ritter M, Ahlers C, Benesch T, PrĂ¼nte C, Schmidt-Erfurth U.

Br J Ophthalmol. 2010 Feb;94(2):185-9. doi: 10.1136/bjo.2008.143974. Epub 2009 Aug 18.

PMID:
19692384
19.

Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular amd.

Keane PA, Chang KT, Liakopoulos S, Jivrajka RV, Walsh AC, Sadda SR.

Retina. 2009 May;29(5):592-600. doi: 10.1097/IAE.0b013e31819b17a5.

PMID:
19289984
20.

Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.

Parravano M, Oddone F, Tedeschi M, Schiano Lomoriello D, Chiaravalloti A, Ripandelli G, Varano M.

Retina. 2009 Mar;29(3):329-34. doi: 10.1097/IAE.0b013e31819093e6.

PMID:
19092732

Supplemental Content

Support Center